Gene Expression in Papillary Thyroid Carcinoma Reveals Highly Consistent Profiles

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2001 Dec 26

PMID 11752453

Citations 133

Authors

Y Huang

M Prasad

W J Lemon

H Hampel

F A Wright

K Kornacker

V LiVolsi

W Frankel

R T Kloos

C Eng

N S Pellegata

A de la Chapelle

Affiliations

Soon will be listed here.

Abstract

Papillary thyroid carcinoma (PTC) is clinically heterogeneous. Apart from an association with ionizing radiation, the etiology and molecular biology of PTC is poorly understood. We used oligo-based DNA arrays to study the expression profiles of eight matched pairs of normal thyroid and PTC tissues. Additional PTC tumors and other tissues were studied by reverse transcriptase-PCR and immunohistochemistry. The PTCs showed concordant expression of many genes and distinct clustered profiles. Genes with increased expression in PTC included many encoding adhesion and extracellular matrix proteins. Expression was increased in 8/8 tumors for 24 genes and in 7/8 tumors for 22 genes. Among these genes were several previously known to be overexpressed in PTC, such as MET, LGALS3, KRT19, DPP4, MDK, TIMP1, and FN1. The numerous additional genes include CITED1, CHI3L1, ODZ1, N33, SFTPB, and SCEL. Reverse transcriptase-PCR showed high expression of CITED1, CHI3L1, ODZ1, and SCEL in 6/6 additional PTCs. Immunohistochemical analysis detected CITED1 and SFTPB in 49/52 and 39/52 PTCs, respectively, but not in follicular thyroid carcinoma and normal thyroid tissue. Genes underexpressed in PTC included tumor suppressors, thyroid function-related proteins, and fatty acid binding proteins. Expression was decreased in 7/8 tumors for eight genes and decreased in 6/8 tumors for 19 genes. We conclude that, despite its clinical heterogeneity, PTC is characterized by consistent and specific molecular changes. These findings reveal clues to the molecular pathways involved in PTC and may provide biomarkers for clinical use.

Citing Articles

Estrogen enhances the proliferation, migration, and invasion of papillary thyroid carcinoma via the ERα/KRT19 signaling axis.

Song Z, Wang Y, Chai F, Zhang J, Lv S, Wang J J Endocrinol Invest. 2024; 48(3):653-670.

PMID: 39453570 PMC: 11876195. DOI: 10.1007/s40618-024-02473-5.

The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer.

Alfandari A, Moskovich D, Weisz A, Katzav A, Kidron D, Beiner M Mol Oncol. 2024; 18(9):2298-2313.

PMID: 38429887 PMC: 11467794. DOI: 10.1002/1878-0261.13612.

Roles and signaling pathways of CITED1 in tumors: overview and novel insights.

Chen W, Jiang J, Gao J, Wang G, Wang R, Lv J J Int Med Res. 2024; 52(1):3000605231220890.

PMID: 38190845 PMC: 10775745. DOI: 10.1177/03000605231220890.

MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer.

Metman M, Jonker P, Sondorp L, van Hemel B, Sywak M, Gill A Eur J Nucl Med Mol Imaging. 2023; 51(8):2384-2394.

PMID: 38017325 PMC: 11178647. DOI: 10.1007/s00259-023-06525-5.

Insight of novel biomarkers for papillary thyroid carcinoma through multiomics.

Liu W, Zhu J, Wu Z, Yin Y, Wu Q, Wu Y Front Oncol. 2023; 13:1269751.

PMID: 37795451 PMC: 10546062. DOI: 10.3389/fonc.2023.1269751.

References

Stoffer S, Van Dyke D, Bach J, Szpunar W, WEISS L . Familial papillary carcinoma of the thyroid. Am J Med Genet. 1986; 25(4):775-82. DOI: 10.1002/ajmg.1320250415. View

Rojeski M, Gharib H . Nodular thyroid disease. Evaluation and management. N Engl J Med. 1985; 313(7):428-36. DOI: 10.1056/NEJM198508153130707. View

Masters B, Kelly E, Quaife C, Brinster R, Palmiter R . Targeted disruption of metallothionein I and II genes increases sensitivity to cadmium. Proc Natl Acad Sci U S A. 1994; 91(2):584-8. PMC: 42993. DOI: 10.1073/pnas.91.2.584. View

Goldgar D, Easton D, Cannon-Albright L, Skolnick M . Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994; 86(21):1600-8. DOI: 10.1093/jnci/86.21.1600. View

Stsjazhko V, Tsyb A, Tronko N, Souchkevitch G, Baverstock K . Childhood thyroid cancer since accident at Chernobyl. BMJ. 1995; 310(6982):801. PMC: 2549173. DOI: 10.1136/bmj.310.6982.801. View

Tanaka T, Umeki K, Yamamoto I, Sakamoto F, Noguchi S, OHTAKI S . CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma. Int J Cancer. 1995; 64(5):326-31. DOI: 10.1002/ijc.2910640508. View

Weiss M, Baruch A, Keydar I, Wreschner D . Preoperative diagnosis of thyroid papillary carcinoma by reverse transcriptase polymerase chain reaction of the MUC1 gene. Int J Cancer. 1996; 66(1):55-9. DOI: 10.1002/(SICI)1097-0215(19960328)66:1<55::AID-IJC10>3.0.CO;2-A. View

MacGrogan D, Levy A, Bova G, Isaacs W, Bookstein R . Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics. 1996; 35(1):55-65. DOI: 10.1006/geno.1996.0322. View

Poblete M, Nualart F, del Pozo M, Perez J, Figueroa C . Alpha 1-antitrypsin expression in human thyroid papillary carcinoma. Am J Surg Pathol. 1996; 20(8):956-63. DOI: 10.1097/00000478-199608000-00004. View

10.

Fernandez P, Merino M, Gomez M, Campo E, Medina T, Castronovo V . Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol. 1997; 181(1):80-6. DOI: 10.1002/(SICI)1096-9896(199701)181:1<80::AID-PATH699>3.0.CO;2-E. View

11.

Takano T, Matsuzuka F, Sumizaki H, Kuma K, Amino N . Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma. Cancer Res. 1997; 57(17):3792-7. View

12.

Lohi J, Leivo I, Owaribe K, Burgeson R, Franssila K, Virtanen I . Neoexpression of the epithelial adhesion complex antigens in thyroid tumours is associated with proliferation and squamous differentiation markers. J Pathol. 1998; 184(2):191-6. DOI: 10.1002/(SICI)1096-9896(199802)184:2<191::AID-PATH991>3.0.CO;2-S. View

13.

Eisen M, Spellman P, Brown P, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-8. PMC: 24541. DOI: 10.1073/pnas.95.25.14863. View

14.

Cintin C, Johansen J, Christensen I, Price P, Sorensen S, Nielsen H . Serum YKL-40 and colorectal cancer. Br J Cancer. 1999; 79(9-10):1494-9. PMC: 2362720. DOI: 10.1038/sj.bjc.6690238. View

15.

Maeda I, Takano T, Matsuzuka F, Maruyama T, Higashiyama T, Liu G . Rapid screening of specific changes in mRNA in thyroid carcinomas by sequence specific-differential display: decreased expression of acid ceramidase mRNA in malignant and benign thyroid tumors. Int J Cancer. 1999; 81(5):700-4. DOI: 10.1002/(sici)1097-0215(19990531)81:5<700::aid-ijc5>3.0.co;2-d. View

16.

Khoor A, Whitsett J, STAHLMAN M, Olson S, Cagle P . Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol. 1999; 30(6):695-700. DOI: 10.1016/s0046-8177(99)90096-5. View

17.

Klugbauer S, Rabes H . The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene. 1999; 18(30):4388-93. DOI: 10.1038/sj.onc.1202824. View

18.

Takano T, Miyauchi A, Yokozawa T, Matsuzuka F, Maeda I, Kuma K . Preoperative diagnosis of thyroid papillary and anaplastic carcinomas by real-time quantitative reverse transcription-polymerase chain reaction of oncofetal fibronectin messenger RNA. Cancer Res. 1999; 59(18):4542-5. View

19.

Scita G, Nordstrom J, Carbone R, Tenca P, Giardina G, Gutkind S . EPS8 and E3B1 transduce signals from Ras to Rac. Nature. 1999; 401(6750):290-3. DOI: 10.1038/45822. View

20.

Ghoshal K, Majumder S, Li Z, Dong X, Jacob S . Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation. J Biol Chem. 2000; 275(1):539-47. DOI: 10.1074/jbc.275.1.539. View